Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration

摘要: Background The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD). Methods This was a retrospective, comparative, consecutive case series 88 unique eyes with fvPEDs neovascular AMD treated anti-VEGF monotherapy for minimum 6 months. All were treatment naive. Diagnosis confirmed retrospectively by fluorescein angiography spectral-domain optical coherence tomography. Exclusion criteria included serous/drusenoid PEDs or patients who switched anti-VEGF. Mean follow-up across all therapies 313.9±85.3 days. Results Average age 80.6 years. Baseline maximum subfoveal PED height 326.8±185.1 μm, 394.5±238.6 μm 258.0±145.3 μm bevacizumab, ranibizumab, respectively (p=0.05). had subretinal fluid, intraretinal fluid combination two at an initial presentation. Central retinal thickness decreased time points compared baseline therapies. Subfoveal bevacizumab 1-month, 3-month 6-month points. Aflibercept reduced more than 1-month 12-month follow-ups (p=0.02 p=0.03, respectively) ranibizumab (p=0.03 p=0.02, respectively). No differences best-corrected visual acuity appreciated any point between drugs. Conclusions There significant reduction baseline. A direct comparison demonstrated beneficial height, albeit inconsistently, favouring aflibercept. no groups point.